These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1007 related articles for article (PubMed ID: 12215068)

  • 1. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM; Noble S; Goa KL
    Drugs; 2002; 62(13):1945-81. PubMed ID: 12215068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spotlight on insulin aspart in type 1 and 2 diabetes mellitus.
    Chapman TM; Noble S; Goa KL
    Treat Endocrinol; 2003; 2(1):71-6. PubMed ID: 15871555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus.
    Reynolds NA; Wagstaff AJ
    Drugs; 2004; 64(17):1957-74. PubMed ID: 15329046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus.
    Wilde MI; McTavish D
    Drugs; 1997 Oct; 54(4):597-614. PubMed ID: 9339963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
    Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
    Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.
    Christiansen JS; Vaz JA; Metelko Z; Bogoev M; Dedov I
    Diabetes Obes Metab; 2003 Nov; 5(6):446-54. PubMed ID: 14617231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
    Davidson J; Vexiau P; Cucinotta D; Vaz J; Kawamori R
    Clin Ther; 2005; 27 Suppl B():S75-88. PubMed ID: 16519039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
    Halimi S; Raskin P; Liebl A; Kawamori R; Fulcher G; Yan G
    Clin Ther; 2005; 27 Suppl B():S57-74. PubMed ID: 16519038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Premixed insulin analogues for the treatment of diabetes mellitus.
    Garber AJ
    Drugs; 2006; 66(1):31-49. PubMed ID: 16398567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics and pharmacodynamics of insulin aspart.
    Lindholm A; Jacobsen LV
    Clin Pharmacokinet; 2001; 40(9):641-59. PubMed ID: 11605714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biphasic insulin aspart in type 2 diabetes mellitus: an evidence-based medicine review.
    Gough SC; Tibaldi J
    Clin Drug Investig; 2007; 27(5):299-324. PubMed ID: 17451279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus.
    Niskanen L; Jensen LE; Råstam J; Nygaard-Pedersen L; Erichsen K; Vora JP
    Clin Ther; 2004 Apr; 26(4):531-40. PubMed ID: 15189750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.
    Hermansen K; Colombo M; Storgaard H; ØStergaard A; Kølendorf K; Madsbad S
    Diabetes Care; 2002 May; 25(5):883-8. PubMed ID: 11978685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW
    Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures.
    Roach P; Woodworth JR
    Clin Pharmacokinet; 2002; 41(13):1043-57. PubMed ID: 12403642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70.
    Ohira M; Endo K; Oyama T; Yamaguchi T; Ban N; Kawana H; Nagayama D; Nagumo A; Saiki A; Murano T; Watanabe H; Miyashita Y; Shirai K
    Metabolism; 2011 Jan; 60(1):78-85. PubMed ID: 20667560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple mealtime administration of biphasic insulin aspart 30 versus traditional basal-bolus human insulin treatment in patients with type 1 diabetes.
    Chen JW; Lauritzen T; Bojesen A; Christiansen JS
    Diabetes Obes Metab; 2006 Nov; 8(6):682-9. PubMed ID: 17026493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis.
    Andrade-Castellanos CA; Colunga-Lozano LE; Delgado-Figueroa N; Gonzalez-Padilla DA
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD011281. PubMed ID: 26798030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biphasic insulin aspart 30 for the treatment of type 1 diabetes mellitus.
    Velásquez-Mieyer PA; Neira CP
    Expert Opin Pharmacother; 2008 Sep; 9(13):2377-82. PubMed ID: 18710361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.